Seied-Reza Seied-Mohammad Doulabi
Seied-Reza Seied-Mohammad Doulabi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Moradi
Department of Otolaryngology, SINA Clinic, Obertshausen, Germany
2 shared publications - Ashkan Sherafat Vaziri
Department of Otolaryngology, SINA Clinic, Obertshausen, Germany
2 shared publications - Mehran Baghi
Department of Otolaryngology, SINA Clinic, Obertshausen, Germany
2 shared publications - Knut Engels
Center for Pathology, Cytology and Molecular Pathology, Neuss, Germany
1 shared publication - Silke Helbig
Department of Otorhinolaryngology, University Hospital Frankfurt, Frankfurt/M, Germany
1 shared publication - Susanne Kriener
Center for Pathology, Cytology and Molecular Pathology, Neuss, Germany
1 shared publication
Latest Publications
- 6 January 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (5) , 2815-2826
Stem cell–based and gene editing strategies in the treatment of congenital and acquired sensorineural hearing loss: a narrative review
Background Sensorineural hearing loss (SNHL) represents the most common sensory deficit in humans and is increasingly prevalent with aging. Despite diverse etiologies, irreversible degeneration of cochlear hair cells and neurons remains a final pathway for auditory decline. Objective This narrative review synthesizes current preclinical and early clinical evidence on gene- and stem cell–based strategies for congenital and acquired SNHL, highlighting translational progress, delivery innovations, and persisting limitations. Methods A structured literature and registry search (PubMed, Embase, Scopus, Web of Science, ClinicalTrials.gov, EudraCT) was conducted using Boolean combinations of disease-, gene-, vector-, and delivery-related terms. From 140 initial records, 46 eligible studies were included after full-text screening. Data were qualitatively analyzed across two streams—human clinical (gene therapy) and preclinical/experimental (gene editing, RNA-based modulation, stem-cell regeneration). Results Two independent first-in-human AAV-mediated OTOF replacement trials in children with DFNB9 demonstrated partial restoration of hearing, establishing the first clinical proof-of-concept for cochlear gene therapy. Preclinical studies confirm durable auditory and vestibular rescue using dual-AAV systems, while CRISPR-based editing, antisense oligonucleotides (ASOs), and RNA interference (RNAi) approaches show mechanistic feasibility. Induced pluripotent stem cells (iPSCs) and inner-ear organoids replicate key developmental pathways, supporting modeling and future cellular repair. Delivery precision via the round window, oval window, and microneedle systems remains the major translational bottleneck. Conclusions Gene- and cell-based approaches are transforming auditory regenerative medicine. Among them, AAV-mediated OTOF replacement has reached clinical validation, whereas CRISPR, ASO/RNAi, and iPSC-derived regeneration continue at advanced preclinical stages. Future success will depend on refining delivery, ensuring long-term safety, and harmonizing ethical and regulatory oversight.
- 6 January 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (5) , 2815-2826
Stem cell–based and gene editing strategies in the treatment of congenital and acquired sensorineural hearing loss: a narrative review
Background Sensorineural hearing loss (SNHL) represents the most common sensory deficit in humans and is increasingly prevalent with aging. Despite diverse etiologies, irreversible degeneration of cochlear hair cells and neurons remains a final pathway for auditory decline. Objective This narrative review synthesizes current preclinical and early clinical evidence on gene- and stem cell–based strategies for congenital and acquired SNHL, highlighting translational progress, delivery innovations, and persisting limitations. Methods A structured literature and registry search (PubMed, Embase, Scopus, Web of Science, ClinicalTrials.gov, EudraCT) was conducted using Boolean combinations of disease-, gene-, vector-, and delivery-related terms. From 140 initial records, 46 eligible studies were included after full-text screening. Data were qualitatively analyzed across two streams—human clinical (gene therapy) and preclinical/experimental (gene editing, RNA-based modulation, stem-cell regeneration). Results Two independent first-in-human AAV-mediated OTOF replacement trials in children with DFNB9 demonstrated partial restoration of hearing, establishing the first clinical proof-of-concept for cochlear gene therapy. Preclinical studies confirm durable auditory and vestibular rescue using dual-AAV systems, while CRISPR-based editing, antisense oligonucleotides (ASOs), and RNA interference (RNAi) approaches show mechanistic feasibility. Induced pluripotent stem cells (iPSCs) and inner-ear organoids replicate key developmental pathways, supporting modeling and future cellular repair. Delivery precision via the round window, oval window, and microneedle systems remains the major translational bottleneck. Conclusions Gene- and cell-based approaches are transforming auditory regenerative medicine. Among them, AAV-mediated OTOF replacement has reached clinical validation, whereas CRISPR, ASO/RNAi, and iPSC-derived regeneration continue at advanced preclinical stages. Future success will depend on refining delivery, ensuring long-term safety, and harmonizing ethical and regulatory oversight.
- 1 November 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (12) , 6393-6404
Comparative evaluation of subtotal and total tonsillectomy in the management of chronic tonsillopharyngitis in adults
Objectives To compare postoperative outcomes of subtotal (intracapsular) and total (extracapsular) tonsillectomy in adults with chronic tonsillopharyngitis, with focus on pain, primary (< 24 h) and secondary (2nd to 14th postoperative day) hemorrhage, hospital stay, and recurrence, and to evaluate the influence of surgical technique (coblation vs. cold dissection). Design Retrospective descriptive-analytical study. Setting Department of Otolaryngology, Ketteler Hospital, Offenbach, Germany. Participants Ninety-seven adults (18–60 years) undergoing subtotal or total tonsillectomy between 2016 and 2021, stratified into four subgroups: subtotal–coblation, subtotal–cold dissection, total–coblation, and total–cold dissection. Main outcome measures Postoperative pain (VAS and WHO scale), primary and secondary hemorrhage, hospital stay, reoperation, and antibiotic use. Results Subtotal tonsillectomy was associated with significantly lower pain scores (P = 0.031) and shorter hospital stay (mean 1.24 ± 0.66 days) compared with total tonsillectomy (mean 4.25 ± 1.25 days, P < 0.001). Coblation also reduced pain compared with cold dissection (P = 0.044). Primary hemorrhage rates did not differ significantly between subtotal and total procedures (6.3% vs. 11.9%, P = 0.28) or between surgical techniques (P = 0.52). In contrast, secondary hemorrhage was more frequent after total tonsillectomy (10.0% vs. 0%, P = 0.004), highest in the total–coblation group (14.6%) and absent in subtotal–cold dissection cases (P = 0.010 for four-group comparison). Reoperation (7.2%) and postoperative antibiotic use showed no significant intergroup differences. Conclusions Subtotal tonsillectomy, particularly when performed with coblation, offers advantages of reduced pain, shorter hospitalization, and lower secondary bleeding risk compared with total tonsillectomy, while maintaining comparable safety regarding primary hemorrhage. These findings support subtotal tonsillectomy as a less invasive, patient-centered alternative in selected adults, although prospective multicenter studies are required to confirm long-term and recurrence outcomes.
- 1 November 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (12) , 6393-6404
Comparative evaluation of subtotal and total tonsillectomy in the management of chronic tonsillopharyngitis in adults
Objectives To compare postoperative outcomes of subtotal (intracapsular) and total (extracapsular) tonsillectomy in adults with chronic tonsillopharyngitis, with focus on pain, primary (< 24 h) and secondary (2nd to 14th postoperative day) hemorrhage, hospital stay, and recurrence, and to evaluate the influence of surgical technique (coblation vs. cold dissection). Design Retrospective descriptive-analytical study. Setting Department of Otolaryngology, Ketteler Hospital, Offenbach, Germany. Participants Ninety-seven adults (18–60 years) undergoing subtotal or total tonsillectomy between 2016 and 2021, stratified into four subgroups: subtotal–coblation, subtotal–cold dissection, total–coblation, and total–cold dissection. Main outcome measures Postoperative pain (VAS and WHO scale), primary and secondary hemorrhage, hospital stay, reoperation, and antibiotic use. Results Subtotal tonsillectomy was associated with significantly lower pain scores (P = 0.031) and shorter hospital stay (mean 1.24 ± 0.66 days) compared with total tonsillectomy (mean 4.25 ± 1.25 days, P < 0.001). Coblation also reduced pain compared with cold dissection (P = 0.044). Primary hemorrhage rates did not differ significantly between subtotal and total procedures (6.3% vs. 11.9%, P = 0.28) or between surgical techniques (P = 0.52). In contrast, secondary hemorrhage was more frequent after total tonsillectomy (10.0% vs. 0%, P = 0.004), highest in the total–coblation group (14.6%) and absent in subtotal–cold dissection cases (P = 0.010 for four-group comparison). Reoperation (7.2%) and postoperative antibiotic use showed no significant intergroup differences. Conclusions Subtotal tonsillectomy, particularly when performed with coblation, offers advantages of reduced pain, shorter hospitalization, and lower secondary bleeding risk compared with total tonsillectomy, while maintaining comparable safety regarding primary hemorrhage. These findings support subtotal tonsillectomy as a less invasive, patient-centered alternative in selected adults, although prospective multicenter studies are required to confirm long-term and recurrence outcomes.